Home

Blueprint Medicines Corporation - Common Stock (BPMC)

80.63
-6.48 (-7.44%)
NASDAQ · Last Trade: Apr 5th, 11:13 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
The Analyst Verdict: Blueprint Medicines In The Eyes Of 14 Expertsbenzinga.com
Via Benzinga · March 20, 2025
This Blueprint Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Mondaybenzinga.com
Via Benzinga · March 17, 2025
13 Analysts Assess Blueprint Medicines: What You Need To Knowbenzinga.com
Via Benzinga · March 3, 2025
Breaking Down Blueprint Medicines: 10 Analysts Share Their Viewsbenzinga.com
Via Benzinga · February 13, 2025
Earnings Scheduled For February 13, 2025benzinga.com
Via Benzinga · February 13, 2025
Analyst Expectations For Blueprint Medicines's Futurebenzinga.com
Via Benzinga · January 27, 2025
IonQ, H&E Equipment Services And ImmunityBio Are Among Top Mid Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?benzinga.com
Explore this week's top-performing mid-cap stocks, including H&E Equipment Services' impressive 100.59% surge following an acquisition announcement by United Rentals. Discover why stocks like SEMrush and Blueprint Medicines also experienced significant gains, impacting investment portfolios positively.
Via Benzinga · January 19, 2025
What Analysts Are Saying About Blueprint Medicines Stockbenzinga.com
Via Benzinga · January 2, 2025
Is NASDAQ:BPMC a Fit for high Growth Investing Strategies?chartmill.com
Why the high growth investor may take a look at BLUEPRINT MEDICINES CORP (NASDAQ:BPMC).
Via Chartmill · December 3, 2024
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Mondaybenzinga.com
Via Benzinga · January 13, 2025
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analystbenzinga.com
JP Morgan initiates coverage on Blueprint Medicines, highlighting Ayvakit's significant growth, 2024 revenue forecast, and potential strategic opportunities.
Via Benzinga · November 14, 2024
Key Takeaways From Blueprint Medicines Analyst Ratingsbenzinga.com
Via Benzinga · November 14, 2024
Analyst Ratings For Blueprint Medicinesbenzinga.com
Via Benzinga · October 24, 2024
9 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · August 13, 2024
15 Analysts Have This To Say About Blueprint Medicinesbenzinga.com
Via Benzinga · July 29, 2024
Expert Ratings For Blueprint Medicinesbenzinga.com
Via Benzinga · June 28, 2024
Assessing Blueprint Medicines: Insights From 16 Financial Analystsbenzinga.com
Via Benzinga · June 7, 2024
Unveiling 18 Analyst Insights On Blueprint Medicinesbenzinga.com
Via Benzinga · May 14, 2024
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · August 8, 2024
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · July 30, 2024
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · May 17, 2024
BPMC Stock Earnings: Blueprint Medicines Beats EPS, Beats Revenue for Q1 2024investorplace.com
BPMC stock results show that Blueprint Medicines beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 2, 2024
C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursdaybenzinga.com
Via Benzinga · May 2, 2024
The Analyst Verdict: Blueprint Medicines In The Eyes Of 7 Expertsbenzinga.com
Via Benzinga · April 26, 2024
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga.com
Via Benzinga · May 1, 2024